Actuate Therapeutics to Unveil Cancer Pipeline Expansion at Citizens Conference
Actuate Therapeutics plans to present at the Citizens Life Sciences Conference on March 10, advancing elraglusib tablet into Phase 1/2 oncology trials launching H2 2026.
ACTUcancer therapypipeline expansion